Evidence map›Paper›PMID 32773012›Full record

ReviewZhongguo fei ai za zhi = Chinese journal of lung cancer2020

[Present and Future of Efficacy Biomarkers in Immune Checkpoint Inhibitors 
of Small Cell Lung Cancer].

Yaning Yang, Yan Wang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Yaning YangDepartment of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, 
Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Yan WangDepartment of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, 
Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inhibitions of immune checkpoints, including programmed cell death 1-programmed cell death-ligand 1 (PD-1-PD-L1) axis, cytotoxic T lymphocyte associated antigen-4, are at the forefront of immunotherapy for small cell lung cancer. However, the survival benefits emerged after three to six months since therapy initiation. A growing body of evidence suggested that the current biomarkers were not consistent and convincing. Here, we review the current biomarkers including PD-L1, tumor mutation burden, DNA damage response pathway. Furthermore, we elucidate the potential biomarkers, such as tumor-infiltrating lymphocytes, circulating tumor cells.
.

Indexed as

AnimalsBiomarkers, TumorCTLA-4 AntigenHumansImmune Checkpoint InhibitorsImmunotherapyLung NeoplasmsSmall Cell Lung CarcinomaBiomarkers, TumorCTLA-4 AntigenImmune Checkpoint InhibitorsEfficacy predictorsLung neoplasmsProgrammed cell death 1Programmed cell death-ligand 1

Identifiers

PMID32773012
PMCPMC7583877

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.